Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8590606rdf:typepubmed:Citationlld:pubmed
pubmed-article:8590606lifeskim:mentionsumls-concept:C0009609lld:lifeskim
pubmed-article:8590606lifeskim:mentionsumls-concept:C1514758lld:lifeskim
pubmed-article:8590606lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:8590606lifeskim:mentionsumls-concept:C0003011lld:lifeskim
pubmed-article:8590606pubmed:issue5lld:pubmed
pubmed-article:8590606pubmed:dateCreated1996-4-4lld:pubmed
pubmed-article:8590606pubmed:abstractTextThe angiotensin II receptor of the AT1-type has been modeled starting from the experimentally determined three-dimensional structure of bacteriorhodopsin as the template. Intermediate 3D structures of rhodopsin and beta 2-adrenergic receptors were built because no direct sequence alignment is possible between the AT1 receptor and bacteriorhodopsin. Docking calculations were carried out on the complex of the modeled receptor with AII, and the results were used to analyze the binding possibilities of DuP753-type antagonistic non-peptide ligands. We confirm that the positively charged Lys199 on helix 5 is crucial for ligand binding, as in our model; the charged side chain of this amino acid interacts strongly with the C-terminal carboxyl group of peptide agonists or with the acidic group at the 2'-position of the biphenyl moiety of DuP753-type antagonists. Several other receptor residues which are implicated in the binding of ligands and the activation of receptor by agonists are identified, and their functional role is discussed. Therefore, a plausible mechanism of receptor activation is proposed. The three-dimensional docking model integrates most of the available experimental observations and helps to plan pertinent site-directed mutagenesis experiments which in turn may validate or modify the present model and the proposed mechanism of receptor activation.lld:pubmed
pubmed-article:8590606pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:languageenglld:pubmed
pubmed-article:8590606pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:citationSubsetIMlld:pubmed
pubmed-article:8590606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8590606pubmed:statusMEDLINElld:pubmed
pubmed-article:8590606pubmed:monthJullld:pubmed
pubmed-article:8590606pubmed:issn0277-8033lld:pubmed
pubmed-article:8590606pubmed:authorpubmed-author:ScheragaH AHAlld:pubmed
pubmed-article:8590606pubmed:authorpubmed-author:MarieJJlld:pubmed
pubmed-article:8590606pubmed:authorpubmed-author:BonnafousJ...lld:pubmed
pubmed-article:8590606pubmed:authorpubmed-author:MaigretBBlld:pubmed
pubmed-article:8590606pubmed:authorpubmed-author:JosephM PMPlld:pubmed
pubmed-article:8590606pubmed:issnTypePrintlld:pubmed
pubmed-article:8590606pubmed:volume14lld:pubmed
pubmed-article:8590606pubmed:ownerNLMlld:pubmed
pubmed-article:8590606pubmed:authorsCompleteYlld:pubmed
pubmed-article:8590606pubmed:pagination381-98lld:pubmed
pubmed-article:8590606pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:meshHeadingpubmed-meshheading:8590606-...lld:pubmed
pubmed-article:8590606pubmed:year1995lld:pubmed
pubmed-article:8590606pubmed:articleTitleA computer modeling postulated mechanism for angiotensin II receptor activation.lld:pubmed
pubmed-article:8590606pubmed:affiliationLaboratoire de Chimie Théorique, Université de Nancy I, Faculté des Sciences, Vandoeuvre-lès-Nancy, France.lld:pubmed
pubmed-article:8590606pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8590606pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8590606pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8590606pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:8590606pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8590606lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8590606lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8590606lld:pubmed